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  An experimental study of‘‘intravenous hemodialysis”was perfor皿ed for the trial of
intracorporeal artificial kidney， and the following results were obtained．
  1． The name ‘‘intravenous hernodia！ysis” was given to the experimental dialysis method
utilizing a cellophane tube retained in the caval vein．
  2． Very little interferlng effect to the circulatory system was observed during the
intravenous hernodialysis． And iVs dialyzing efiiciency． was estiinated to be somewhat lower
than peritoneal dialysis．
  3． Dogs were able to tolerate for a long time dialysis of ，12 hours， and the dialyzing tube
could be retained in the caval vein of dogs for a long Period of tirnes， up to 30r 4エnonths．
  4． The results of in vil’ro experiments indicated that sufficient amount of urea nitrogen
was removed by intravenous hemodialysis as well as in vivo experiments， but removal of
creatinine was not sufficient．
  5． Although there are many problems to be solved concerning the development of
intracorporeal implantable artificial kidney， it was considered that intravenous hemodialysis
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 1． 尿毒症血類似液状のurea－N， creatilline，1ac－
tose各濃度の透析による変化
 2．透析液中へのurea－N， creatinine， lactoseの
移行
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Fig・5．静脈内血液透析の全身血行動態におよぼす影
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Fig・6．静脈内血液透析の全身血行動態におよぼす影




























       ［＝＝＝＝ゴ 1000ml／hf司限流量
       一無制限流量
       一一ヨ腹膜灌流












   O 1 2 3 4 5 6 7 8 9 10 11 12 hrs，
Fig．7，静脈内血液透析の全身血行動態におよぼす影
    響 （2，000m1／h）
          1000ml／h制限流量
  ロ＼99、・＼
  “’1幽戦脚、＼・＼
      ヘ ロムヒ          ロコ      u〈’・・．．   ＼x＼ 2000ml／h
       ヘ コムコ              コの        蟄㌔無制限慮、一一楓一
                   ＼×50     腹膜灌流
   C） 1 2 3 ’4 5 6 7 B 9 ］O ll 12 hrs
































































       （5日目）
    ガ〆   〆、瓢轟誕ボ
Fig．10．セロファン膜の血液成分の付着状態





Fig．11． Case 4 autopsy所見







Fig．12． Case 5 Venacavograph（第103日目）
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Fig． 14．
     腹腔内透析液
腹膜潅流の全身血行動態におよぼす影響
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 （口）Creatinineの変化
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Fig．16．透析液中へ移行した溶質の変化
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